Cynapsus Therapeutics Now Covered by M Partners (CTH)
Analysts at M Partners started coverage on shares of Cynapsus Therapeutics (CVE:CTH) in a research report issued to clients and investors on Tuesday, AnalystRatings.Net reports. The firm set a “buy” rating and a C$1.90 price target on the stock. M Partners’ price objective indicates a potential upside of 115.91% from the company’s current price.
Cynapsus Therapeutics Inc is a specialty pharmaceutical company developing non-injectable delivery of apomorphine to be used as a rescue therapy for off motor symptoms of Parkinson’s disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.